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Patients undergoing the complex treatment for hematological malignancies are exposed
to a high physiological and psychological distress inducing fatigue and physical inactivity.
In line with cancer-related metabolic changes patients are predisposed for skeletal
muscle mass loss that leads to a functional decline, affects therapeutic success, and
quality of life. Benefits of physical exercise and nutritional interventions on muscle
maintenance are observed in solid cancer patients, but marginally investigated in
patients with hematological cancer. We here studied the effects of a combined
supportive exercise and nutrition intervention using whole-body electromyostimulation
(WB-EMS) training and individualized nutritional support in patients actively treated
for hematological malignancy. In a controlled pilot trial, 31 patients (67.7% male;
58.0 ± 16.7 years) with various hematological cancers were allocated to a control
group (n = 9) receiving nutritional support of usual care regarding a high protein
intake (>1.0 g/kg/d) or to a physical exercise group (n = 22) additionally performing
WB-EMS training twice weekly for 12 weeks. Bodyweight and body composition
assessed by bioelectrical impedance analysis were measured every 4 weeks. Physical
function, blood parameters, quality of life and fatigue were assessed at baseline and
after 12 weeks. No WB-EMS-related adverse effects occurred. Patients attending the
exercise program presented a higher skeletal muscle mass than controls after 12-weeks
(1.51 kg [0.41, 2.60]; p = 0.008). In contrast, patients of the control group showed
a higher fat mass percentage than patients of the WB-EMS group (−4.46% [−7.15,
−1.77]; p = 0.001) that was accompanied by an increase in serum triglycerides in
contrast to a decrease in the WB-EMS group (change ± SD, control 36.3 ± 50.6 mg/dl;
WB-EMS −31.8 ± 68.7 mg/dl; p = 0.064). No significant group differences for
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lower limb strength, quality of life, and fatigue were detected. However, compared to
controls the WB-EMS group significantly improved in physical functioning indicated by
a higher increase in the 6-min-walking distance (p = 0.046). A combined therapeutic
intervention of WB-EMS and protein-rich nutritional support seems to be safe and
effective in improving skeletal muscle mass and body composition in hematological
cancer patients during active oncological treatment.
Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT02293239.
Keywords: body composition, physical function, whole-body electromyostimulation, exercise, nutrition, skeletal
muscle mass, hematological malignancies, cancer
INTRODUCTION
With an increasing trend, 40,000 newly diagnosed cases of
malign hematological diseases were registered and accounted
for approximately 19,000 deaths in Germany in 2013 (Robert-
Koch-Institut, 2016). The main malignant neoplasms comprise
leukemia, Hodgkin and Non-Hodgkin lymphoma and multiple
myeloma. Treatment regimens for affected patients are complex
involving high-dose chemotherapy and total-body irradiation
probably before or followed by hematopoietic stem cell
transplantation. Even though improved therapy modalities
had increased the survival of the patients in the past years,
adverse therapy effects are still responsible for many deaths
in hematological patients (Copelan, 2006; Othus et al., 2014;
Buckley et al., 2015). Side effects linked to the disease as well
as therapy complications such as anemia, a high susceptibility
for infections, fatigue or Graft-versus-Host-Disease (GvHD) lead
to a decreased physical activity – especially in patients with
a long inpatient treatment (Danaher et al., 2006; Morishita
et al., 2012a; Wiskemann et al., 2014). As a consequence
of physical inactivity, the catabolic effects of cytotoxic and
immunosuppressive therapies, as well as the metabolic changes
and myopathy induced by a long-term glucocorticoid treatment
(Gupta and Gupta, 2013; Macedo et al., 2016), hematological
cancer patients undergo unfavorable body composition changes
during the active treatment period (Greenfield et al., 2014). While
fat mass increases during and after the oncological therapy,
muscle mass declines. Those alterations are hardly reversible
into the pre-illness and pre-treatment status and may result
in sarcopenic obesity that may predispose patients for other
metabolic diseases in future (Morishita et al., 2012b; Orgel et al.,
2016; Xiao et al., 2016). Treatment-associated muscle weakness
also leads to functional declines that can be still observed in
survivorship (Inaba et al., 2012; Hung et al., 2013). Muscle
wasting and physical deconditioning thereby not only enhance
symptoms of fatigue, but also substantially impair patients’
quality of life, reduce therapy options and worsen prognosis
(Danaher et al., 2006; Mosher et al., 2009; Morishita et al.,
2012a,b; Lanic et al., 2014; Chu et al., 2017).
Adverse disease and treatment effects such as nausea,
vomiting, diarrhea and mucositis can impair nutritional intake
and are responsible for the high numbers of hematological
patients that are at nutritional risk – particularly in patients
who received stem cell transplantation (Liu et al., 2016).
Thus, an adequate individual nutritional support is highly
emphasized for hematological cancer patients as malnutrition
could increase mortality (Calleja Fernandez et al., 2015).
Previous studies clearly suggest the feasibility of exercise
intervention in hematological cancer patients to stabilize
muscular status, body composition and improve physical activity
(Liu et al., 2009). However, most studies were conducted as post-
treatment rehabilitation interventions. A primary investigation of
clinically relevant outcomes such as changes in skeletal muscle
mass during treatment has been neglected so far. Treatment-
related effects including fatigue and physical discomfort, but
also bone lesions as a complication of multiple myeloma, may
hinder actively treated patients to enter time-consuming and
strenuous physical exercise programs. We therefore tested the
feasibility of the innovative strength training method of whole-
body electromyostimulation (WB-EMS) in hematological cancer
patients undergoing treatment. The WB-EMS technology enables
a simultaneous muscle contraction of all large muscle groups
that is additionally supported by easy-to-perform dynamic
exercises, as we described in detail previously (Schink et al.,
2018). Observed benefits of a dual intervention of WB-EMS and
individualized nutritional support on muscle mass in patients
with advanced solid cancers (Schink et al., 2018), led us to the
primary hypothesis that this combined approach is also feasible in
hematological patients and may show better effects on stabilizing
or even increasing skeletal muscle mass than a dietary support
alone. Within this multimodal approach we also investigated
the effect of the exercise and nutrition therapy on objective
outcomes including bodyweight and body composition, physical
functioning, hematological and blood chemistry parameters as
well as on patient-reported quality of life and fatigue.
MATERIALS AND METHODS
Patients
Adult patients (≥18 years) with confirmed diagnosis of a
malignant hematological disease undergoing active treatment
at initial evaluation were considered eligible for the study.
This included patients with or without prior or subsequent
hematopoietic stem cell transplantation (HSCT) and patients
who were treated for acute GvHD as an adverse effect of
HSCT. To enable the conduction of exercises patients had
to display a Karnofsky performance status ≥60 at baseline.
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Patients were excluded from study participation when they
already participated in other nutritional or physical exercise
trials and consumed anabolic drugs, recently. An study exclusion
was also necessary if patients experienced acute cardio-vascular
events, suffered from epilepsy, severe neurological diseases or
skin lesions within the area of electrodes, underwent surgery in
the last 3 months, presented acute vein thrombosis, a cardiac
pace-maker or conductive implants or in case of pregnancy
as those conditions would exclude a WB-EMS application and
bioelectrical impedance analysis measurement (Schink et al.,
2018).
The declaration of the written informed consent to participate
was obtained from every patient before his inclusion into the
study. The study was conducted according to the guidelines
of the Declaration of Helsinki. The protocol of this study
was approved by the ethics committee of the Friedrich–
Alexander University Erlangen–Nürnberg (Reg.Nr.155_13B) and
registered at clinicaltrials.gov (NCT02293239). Participants of the
present trial were recruited from the Department of Medicine
5 – Haematology and Oncology at the University Hospital
Erlangen during November 2013 and March 2017. All baseline
and outcome assessments, the WB-EMS exercise program,
dietary counseling and data collection were performed at the
Department of Medicine 1 – Gastroenterology, Pneumology and
Endocrinology, Hector-Center for Nutrition, Exercise and Sports
at the University Hospital Erlangen.
Study Design
The pilot study was conducted as a two-armed prospective
controlled clinical trial. After baseline assessment patients were
either allocated to a physical exercise group regularly performing
a WB-EMS training (WB-EMS group) or to a control group
without any exercise intervention. Both groups received the same
nutritional support during the study. Allocation to the study
group was limited by the patients’ ability to attend the exercise
program twice weekly, as described previously (Schink et al.,
2018). In case of inability due to logistical aspects, patients were
allocated to the control group resulting in an approximately
2:1 partition favoring the WB-EMS group. For each patient the
duration of the study intervention was 12 weeks. Patients and
outcome assessing personnel were not blinded.
Dietary Support
The nutritional risk of the recruited study patients was assessed
at baseline and documented by the nutritional risk screening
(NRS-2002) (Kondrup et al., 2003). Patients who scored greater
or equal three points were assumed to be at nutritional risk
caused by low body mass index, decreased food intake and/or
prior involuntary weight loss (Kondrup et al., 2003). The dietary
support and monitoring of the nutritional intake by weekly
24 h-dietary records (Freiburger Ernährungsprotokoll; Nutri-
Science GmbH, Freiburg) during the study have been described
previously (Schink et al., 2018). Briefly, dietary intake was
analyzed by Prodi R©6 (Nutri-Science GmbH, Freiburg) and a
certified dietician instructed/motivated patients by face-to-face
conversation to achieve a daily protein intake of >1.0 g/kg and
caloric intake of at least 25 kcal/kg bodyweight in regard to
current dietary recommendations for patients with malignant
diseases (Arends et al., 2015, 2016). As a precautionary measure,
patients suffering from renal insufficiency or displaying high
serum creatinine concentrations (women, >1.0 mg/dl; men,
>1.2 mg/dl) were instructed not to exceed a daily protein intake
of 1.0 g/kg in acute or 1.2 g/kg in chronic renal disease (Arends
et al., 2016). Supplemental nutrition in form of protein/amino
acid-rich oral supplements or parenteral nutrition (Olimel 5.7%
E, Baxter Germany, Munich) was provided to patients with
insufficient or impaired nutrient intake.
To assess the compliance to the dietary recommendations
proportions of patients who achieved only a normal
(<25 kcal/kg/d; ≤1.0 g/kg/d) or an increased (≥25 kcal/kg/d;
>1.0 g/kg/d) protein and energy intake were calculated.
Physical Exercise Program
Study intervention included a physical exercise program in the
form of a regular WB-EMS training over a period of 12 weeks.
The conduction of the WB-EMS training and exercises were
detailed described previously (Schink et al., 2018). Electrical
muscle stimulation was applied by bipolar impulses at a
frequency of 85 Hz and pulse width of 350 µs mediating a
stimulation for 6 s followed by a 4 s stimulation rest. Here,
muscles of the upper legs, upper arms, bottom, abdomen,
chest, lower back, upper back, and latissimus dorsi have been
stimulated. The supervised WB-EMS training was conducted
twice a week for 20 min/session and comprised a sequence of light
dynamic and easy-to-perform physical exercises that supported
the activation of the mentioned muscle groups (Schink et al.,
2018). WB-EMS equipment was purchased from Miha bodytec
(Miha bodytec GmbH, Gersthofen).
Study Outcomes
Assessments
Demographic data were collected by an anamnesis questionnaire
and medical records. Assessments of study outcomes on body
composition were performed at baseline, in week 4, week 8
and at study end after 12 weeks of study intervention. Blood
parameters, physical functioning and patient-reported quality of
life and fatigue were assessed at baseline and study end.
The adherence of the patients to the WB-EMS training was
registered by the supervising physiotherapists at each exercise
session. Exercise adherence rate of the patients who completed
the 12-week period of the study was calculated by the number of
performed trainings from a total of 24 WB-EMS trainings.
Body Composition, Physical Function, and Quality of
Life
The primary outcome was the change of skeletal muscle mass
assessed by bioelectrical impedance analysis – BIA (seca mBCA
515; Seca GmbH & Co., KG, Hamburg) (Bosy-Westphal and
Jensen, 2017). Secondary endpoints of bodyweight and body
composition including fat mass percentage and phase angle were
also assessed by BIA.
Physical functioning and endurance were assessed by the
6-min-walk test (Schmidt et al., 2013). Functioning and strength
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of the lower limbs was indirectly determined by the 30 s sit-to-
stand (STS) test (Jones et al., 1999). Physical performance status
was determined by Karnofsky-Index (Karnofsky and Burchenal,
1949).
Patient-reported quality of life was evaluated by the European
Organisation for Research and Treatment of Cancer Quality of
Life Questionnaire – C30 (EORTC QLQ-C30) (Aaronson et al.,
1993). Here, a higher score in global health and functional scales
indicate a better quality of life while high scores in symptom
scales hint toward a higher symptomatic burden. An additional
assessment of fatigue was done by the use of the Functional
Assessment of Chronic Illness Therapy – Fatigue Scale that
indicates less fatigue and better function by a higher score
(13-item FACIT Fatigue Scale) (Lai et al., 2003).
Analysis of Blood Samples
Blood samples were collected at baseline and after 12 weeks
of intervention by puncture of the arm vein or blood values
were extracted from the documented routine blood sampling
undertaken during the oncological treatment. The analysis of
nutritional and inflammatory blood markers (normal values:
C-reactive protein, CRP<5 mg/l; albumin 35–55 g/l; total protein
66–83 g/l; triglycerides 50–200 mg/dl; creatinine 0.51–1.17 mg/dl;
lactate dehydrogenase, LDH <250 U/l) and hematological
parameters (leukocytes 4.4–11.3 × 103/µl, thrombocytes 150–
300 × 103/µl, hematocrit 35–48%, hemoglobin 11.5–18.0 g/dl,
erythrocytes 4.1–6.0 × 106/µl) was carried out by the diagnostic
laboratories of the University Hospital Erlangen.
Statistical Analysis
Descriptive data are presented as means ± standard deviations
(SD) for continuous variables and count and percentages for
categorical variables. Laboratory variables are expressed as
median with range. Normal distribution of data was tested by
Shapiro–Wilk test. Baseline differences between study groups
were analyzed by Pearson’s chi-squared test and Fisher’s exact
test, where appropriate, for categorical variables. Continuous
variables were analyzed by independent-samples t-test, Welch-
test or Mann–Whitney U-test, where appropriate. Similarly,
comparisons between patients who completed and not completed
the study were conducted.
To evaluate the effect of WB-EMS intervention on skeletal
muscle mass, bodyweight, and body composition throughout the
study course, linear mixed models (LMM) were generated. LMM
allow the analysis of longitudinal data with missing samples that
is common for clinical trials including serious ill patients with
expected high dropout rates and thus follows the intent-to-treat
approach (Chakraborty and Gu, 2009; West, 2009; Peters et al.,
2012). The LMM were fitted for each outcome using a patient-
specific random intercept. To control for baseline differences,
the baseline value of each outcome was included in the models.
Time and a time-group interaction to estimate the intervention
effect on the study outcome over time were included as fixed
effects. As part of a sensitivity analysis, we also assessed fixed
effects adjusted for age, gender, diagnosis of the hematological
malignancy and glucocorticoid intake. Results are presented as
parameter estimates with 95% confidence intervals (95% CI).
To assess an association between protein intake and changes in
skeletal muscle mass a Pearson correlation analysis was carried
out for both study groups with patients presenting skeletal muscle
mass data after 12 weeks. Secondary outcomes only assessed at
baseline and after 12 weeks were analyzed for all patients with
pre- and post-intervention data. Pre- to post-test changes were
compared by the use of independent-samples t-test or Mann–
Whitney U-test, where appropriate, and presented as mean± SD.
Statistical analysis was conducted using SPSS version 21 (IBM
SPSS Statistics, Ehningen, Germany) and Prism 7.00 (GraphPad
Software Inc., La Jolla, CA, United States). Two-sided p-value
<0.05 was considered as statistically significant. Due to the
exploratory character of this pilot study, no correction for
multiple testing was applied.
RESULTS
Participants
Baseline Characteristics
Thirty-one patients undergoing active treatment for acute
myeloid leukemia (AML), Hodgkin lymphoma, Non-Hodgkin
lymphoma (NHL), multiple myeloma and/or associated acute
GvHD were recruited for the trial (Figure 1).
Participants’ baseline characteristics are presented in
Table 1. Study groups were well balanced in demographic and
anthropometric baseline variables with a higher percentage
of male participants in both study groups. No significant
group differences between body composition parameters and
functional status were observed at study entry. Patients of both
groups showed a high mean body mass index (>25.0 kg/m2)
and 61.3% of all recruited patients were defined as overweight
or obese regarding the WHO classification of the nutritional
status (World Health Organization [WHO], 2000). The obese
phenotype of the patients was underlined by a high fat mass
percentage (>27.0% fat mass) and increased metabolic risk
factors indicated by higher serum triglyceride concentrations
(>170 mg/dl). Nevertheless, approximately two-third of the
study patients in both groups were at nutritional risk (NRS
score ≥3) due to decreased food intake or unintended disease-
or treatment-related weight loss indicating the demand of
nutritional support at baseline. However, only one patient of
the control and three patients of the WB-EMS group had to be
supported by artificial nutrition in addition to the support by
nutritional counseling. Patients of both study groups reported
comparable quality of life (p = 0.286) and fatigue severity
(p = 0.284) at the beginning of the study. Disease characteristics
including diagnosis and current oncological treatment of the
hematological cancer were not significantly different at baseline
except of a significantly lower median leukocyte count in the
control group compared to the WB-EMS group. Approximately
one-third of the study patients of each group exhibited osteolytic
lesions as a consequence of myeloma bone marrow infiltration.
Nutritional Intake
During the study the nutritional goals regarding a high daily
caloric (≥25 kcal/kg) and protein (>1.0 g/kg) intake were
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FIGURE 1 | Patient flowchart. The flowchart shows the number of the allocated patients and the number of patients who dropped out during study course with
dropout reasons and the number of patients who completed the whole intervention period of 12 weeks. During the study, body composition analysis was missed by
1 patient of the WB-EMS group at week 4 and 1 control and 2 WB-EMS patients at week 8. WB-EMS, whole-body electromyostimulation.
achieved by approximately 90% of all recruited patients of the
control and the WB-EMS group (Table 2). Both study groups
exceeded the minimum aimed dietary intake by a mean daily
protein intake of 1.4 g/kg and a mean daily caloric intake more
than 30 kcal/kg. Of note, two patients of the WB-EMS group and
one control patient failed to document dietary intake and were
therefore unavailable for the nutritional analysis.
Feasibility and Exercise Adherence
Patients’ flow chart and dropout reasons are presented in
Figure 1. During the trial, 3 patients of the control and 13 patients
of the WB-EMS group prematurely withdrew from the study
leading to a dropout rate of 33.3% for the control and 59.1%
for the WB-EMS group (p = 0.252). Reason for study dropout
in the WB-EMS group was mainly due to treatment-related
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TABLE 1 | Demographic and disease characteristics of the included patients.
Control WB-EMS
Parameter (n = 9) (n = 22) p-Valuea
Gender 1.000
Male 6 (66.7) 15 (68.2)
Female 3 (33.3) 7 (31.8)
Mean age 57.2 ± 14.1 54.8 ± 17.9 0.881
Functional status
Karnofsky-Index 73.3 ± 8.7 75.9 ± 11.4 0.548
6-min walking distance (m) 504.7 ± 66.1 494.0 ± 142.2 0.832
Sit-to-stand repetitions 12.7 ± 3.7 12.6 ± 5.1 0.953
Anthropometry
BMI [kg/m2]2 25.8 ± 3.1 25.4 ± 4.1 0.810
Underweight (<18.5 kg/m2) 0 (0.0) 2 (9.1) 0.479
Normal weight (18.5–24.9 kg/m2) 4 (44.4) 6 (27.3)
Overweight/Obesity (≥25.0 kg/m2) 5 (55.6) 14 (63.6)
Fat mass index (kg/m2) 7.1 ± 2.1 7.4 ± 3.1 0.829
Fat free mass index [kg/m2] 18.6 ± 2.1 18.3 ± 2.4 0.741
Body composition
Skeletal muscle mass [kg] 25.7 ± 6.6 24.7 ± 6.3 0.704
Fat mass [%] 27.4 ± 6.1 27.6 ± 9.7 0.578
Hydration [%; ECW:ICW] 87.6 ± 15.1 86.6 ± 10.3 0.823
Phase angle [◦] 4.4 ± 1.1 4.2 ± 0.9 0.625
Nutritional status
Nutritional risk screening 1.000
(NRS-2002)
<3 3 (33.3) 8 (36.4)
≥3 6 (66.7) 14 (63.6)
Weight loss [%] 5.2 ± 4.0 4.3 ± 4.5 0.334
≤5% 4 (44.4) 16 (72.7) 0.217
>5% 5 (55.6) 6 (27.3)
Nutritional therapy 1.000
Only dietary counseling 8 (88.9) 19 (86.4)
Oral supplementation 1 (11.1) 3 (13.6)
Parenteral nutrition 0 (0.0) 0 (0.0)
Quality of life
EORTC QLQ-C30 global 45.3 ± 16.5 54.5 ± 20.0 0.286
health
FACIT-fatigue scale 27.3 ± 10.4 32.6 ± 11.1 0.284
Disease characteristics
Diagnosis 0.272
Acute myeloid leukemia 3 (33.3) 2 (9.1)
Hodgkin lymphoma 2 (22.2) 3 (13.6)
Non-Hodgkin-lymphoma 1 (11.1) 7 (31.8)
Multiple myeloma 3 (33.3) 10 (45.5)
Oncological treatment1
Chemotherapy 7 (77.8) 9 (40.9) 0.113
Radiotherapy 1 (11.1) 2 (9.1) 1.000
Targeted/immunotherapy 6 (66.7) 15 (68.2) 1.000
Glucocorticoid intake 6 (66.7) 17 (77.3) 0.660
Immunosuppression 5 (55.6) 15 (68.2) 0.683
Previous HSCT 1 (11.1) 6 (27.3) 0.639
Osteolytic lesion 3 (33.3) 7 (31.8) 1.000
Number of medications 5.9 ± 3.6 7.2 ± 6.0 0.881
(Continued)
TABLE 1 | Continued
Control WB-EMS
Parameter (n = 9) (n = 22) p-Valuea
Comorbidities1
Cardiovascular disease 3 (33.3) 6 (27.3) 1.000
Pulmonary disease 0 (0.0) 2 (9.1) 1.000
Liver disease 1 (11.1) 1 (4.5) 0.503
Renal failure 2 (22.2) 1 (4.5) 0.195
Thyroid disease 2 (22.2) 4 (18.2) 1.000
Diabetes mellitus 0 (0.0) 1 (4.5) 1.000
Hypertension 4 (44.4) 6 (27.3) 0.417
Hyperlipidemia 1 (11.1) 3 (13.6) 1.000
Acute GvHD 0 (0.0) 2 (9.1) 1.000
Laboratory values
Leukocytes [×103/µl] 3.60 (1.30–11.40) 5.45 (2.10–27.90) 0.016
Thrombocytes [×103/µl] 137.0 (56.0–367.0) 183.5 (26.0–383.0) 0.676
Erythrocytes [×106/µl] 3.77 (2.93–4.97) 3.77 (2.71–4.85) 0.996
Hematocrit [%] 32.9 (26.9–41.7) 34.1 (27.8–43.3) 0.607
Hemoglobin [g/dl] 12.1 (9.2–13.9) 11.8 (8.7–14.3) 0.769
Albumin [g/l] 40.6 (35.5–43.6) 39.1 (24.7–46.2) 0.290
C-reactive protein [mg/l] 1.9 (0.6–16.7) 3.4 (0.2–82.9) 0.749
Creatinine [mg/dl] 0.94 (0.60–1.77) 0.86 (0.61–3.11) 0.334
Lactate dehydrogenase 220.0 (48.0–1101.0) 233.5 (103.0–638.0) 0.593
[IU/l]
Triglycerides [mg/dl] 174.0 (51.0–695.0) 187.0 (79.0–319.0) 0.377
Data are presented in numbers and proportions (%) and as mean ± standard
deviation. Laboratory values are expressed as median and range (min to max).
aBaseline comparison between WB-EMS and control group assessed by Pearson’s
chi-squared and Fisher’s exact test, respectively, for categorical variables and
independent-samples t-test, Welch’s test or Mann–Whitney U-test for continuous
variables. Statistically significant differences are indicated by p < 0.05 and
marked in bold type. 1Numbers of patients for comorbidities and oncological
treatment include also patients with several comorbidities and combined anticancer
therapies. 2WHO categories to determine nutritional status (World Health
Organization [WHO], 2000). WB-EMS, whole-body electromyostimulation; BMI,
body mass index; ECW, extracellular water; ICW, intracellular water; GvHD,
Graft-versus-Host-Disease; HSCT, hematopoietic stem cell transplantation.
toxicities and clinical deterioration. Two patients of the WB-
EMS group who prematurely terminated the study suffered from
acute GvHD. However, reasons were not significantly different
between study groups (p = 0.686). Patients who were not able
to continue the study had a significantly higher drug intake
(8.9 ± 6.0 vs. 4.7 ± 3.7; p = 0.026) as well as a higher leukocyte
count (9.0 ± 7.2 × 103/µl vs. 4.6 ± 2.4 × 103/µl; p = 0.033)
in line with lower albumin concentrations (37.7 ± 5.1 g/l vs.
40.7 ± 3.5 g/l; p = 0.073) than patients who completed the study.
Further, they showed a less social functioning assessed by the
EORTC QLQ-C30 (44.9 ± 19.8 vs. 65.5 ± 21.2; p = 0.015).
No significant differences of the patients who dropped out
between the two study groups were detected. Remarkably, no
WB-EMS related side-effects or discomfort appeared despite a
small muscular aching comparable to other strength training
methods. Patients of the WB-EMS group who completed the 12-
week intervention period attended in average 18.6 ± 3.5 from a
total of 24 training sessions leading to a mean exercise adherence
rate of 77.3± 14.5%.
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TABLE 2 | Nutritional intake during study course of the included patientsa.
Study group
Control WB-EMS
(n = 8) (n = 20) p-Valueb
Mean daily nutrient/caloric
intake [per kg bodyweight]
Carbohydrates (g) 3.4 ± 0.8 3.6 ± 1.2 0.650
Fat (g) 1.4 ± 0.5 1.4 ± 0.5 0.636
Protein (g) 1.4 ± 0.3 1.4 ± 0.2 0.733
Energy (kcal) 32.8 ± 8.7 34.2 ± 7.5 0.669
Achievement of dietary
goals
Energy group 1.000
<25 kcal/kg 1 (12.5) 2 (10.0)
≥25 kcal/kg 7 (87.5) 18 (90.0)
Protein group 1.000
≤1.0 g/kg 1 (12.5) 2 (10.0)
>1.0 g/kg 7 (87.5) 18 (90.0)
Data are presented in numbers and proportions (%) and as mean ± standard
deviation. aDietary data of two patients of the WB-EMS group and one patient
of the control group were unavailable. bCategorical variables were analyzed
by Fisher’s exact test and continuous variables by independent-samples t-test.
WB-EMS, whole-body electromyostimulation.
Body Composition
During the study course of 12 weeks patients of the WB-EMS
group showed an increase in skeletal muscle mass, while a
reduction in muscle mass was observed for control patients
(Figure 2A). This resulted in a significant estimated mean
difference between the groups of 1.21 kg [0.32, 2.10] at week 4,
1.49 kg [0.41, 2.57] at week 8, and 1.51 kg [0.41, 2.60] at the end of
the 12-week intervention period favoring the combined exercise
and nutrition intervention (p < 0.01; Table 3). In line with this,
fat free mass index (FFMI) was significantly higher in the WB-
EMS group compared to controls after 12 weeks (p < 0.001;
Figure 2D and Table 3). Both study groups tended to increase in
bodyweight (Figure 2C), but in contrast to the WB-EMS group,
the bodyweight gain in controls was characterized by an increase
in fat mass indicated by an increase of the body fat percentage
(Figure 2B) and fat mass index (FMI; Figure 2E). This led to
an estimated negative effect of the WB-EMS group on body fat
percentage and FMI (p< 0.01 at week 12; Table 3). No significant
mean group differences were observed for the parameter of
phase angle over time (p > 0.05; Table 3). A trend toward an
increased phase angle in controls (Figure 2F) is suggested to
be rather a result of treatment-related changes in body water
distribution of the extracellular water (ECW) to the intracellular
water (ICW) (Hydration, Table 3) than in body cell mass. Of note,
an additional sensitivity analysis adjusting the LMM’s for age,
gender, cancer diagnosis, and glucocorticoid treatment did not
reveal appreciable alterations of the estimated treatment effects
and significances (Table 3).
Pearson correlation analysis yielded a significant strong
positive correlation between an increase in skeletal muscle
mass and the amount of protein intake in the WB-EMS group
(r = 0.682; p = 0.043), while no significant relationship between
protein intake and muscle mass gain was observed for the
control group (r = −0.609; p = 0.275; Figure 3). The significant
correlation for the WB-EMS group was also observed for muscle
mass changes in week 4 and week 8 (r > 0.600), but not in the
control group (data not shown).
FIGURE 2 | Changes in body composition during the 12-week intervention period. Unadjusted estimated marginal means with 95% confidence intervals of the body
composition parameters (A) skeletal muscle mass, (B) fat mass percentage, (C) bodyweight, (D) FFMI, (E) FMI, and (F) phase angle are illustrated for the control
group and the WB-EMS group over the 12-week study course. WB-EMS, whole-body electromyostimulation; FMI, fat mass index; FFMI, fat free mass index.
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TABLE 3 | Linear mixed model analysis estimating the unadjusted and adjusteda effect (group × time) of the combined WB-EMS and nutrition intervention on
anthropometry, and body composition over the 12-week study course compared to the usual care control group.
Estimated effect of WB-EMS intervention compared to controlsb
Estimate [95% CI] p-Value Estimate [95% CI] p-Value Estimate [95% CI] p-Value
Outcome measure Model Week 4 Week 8 Week 12
Anthropometry
Bodyweight [kg] Unadjusted 0.78 [−0.83, 2.40] 0.336 0.99 [−0.98, 2.95] 0.321 0.85 [−1.15, 2.85] 0.399
Adjusteda 0.80 [−0.80, 2.41] 0.320 1.08 [−0.88, 3.03] 0.276 0.94 [−1.04, 2.93] 0.347
FMI [kg/m2] Unadjusted −0.66 [−1.28, −0.04] 0.039 −0.64 [−1.39, 0.10] 0.091 −1.13 [−1.89, −0.38] 0.004
Adjusteda −0.75 [−1.42, −0.07] 0.030 −78 [−1.57, 0.01] 0.054 −1.21 [−2.02, −0.41] 0.004
FFMI [kg/m2] Unadjusted 1.00 [0.43, 1.59] 0.001 1.06 [0.35, 1.76] 0.004 1.53 [0.82, 2.25] 0.000
Adjusteda 1.10 [0.53, 1.66] 0.000 1.22 [0.53, 1.91] 0.001 1.70 [1.01, 2.41] 0.000
Body composition
SMM [kg] Unadjusted 1.21 [0.32, 2.10] 0.008 1.49 [0.41, 2.57] 0.007 1.51 [0.41, 2.60] 0.008
Adjusteda 1.36 [0.48, 2.24] 0.003 1.75 [0.68, 2.81] 0.002 1.77 [0.68, 2.85] 0.002
FM [%] Unadjusted −2.89 [−5.08, −0.70] 0.011 −2.60 [−5.25, 0.05] 0.054 −4.46 [−7.15, −1.77] 0.001
Adjusteda −3.30 [−5.59, −1.01] 0.006 −3.27 [−6.00, 0.53] 0.020 −4.91 [−7.68, −2.13] 0.001
PhA [◦] Unadjusted −0.09 [−.29, 0.12] 0.396 −0.07 [−0.32, 0.18] 0.572 −0.15 [−0.40, 0.11] 0.256
Adjusteda −0.10 [−0.32, 0.13] 0.389 −0.07 [−0.33, 0.20] 0.614 −0.14 [−0.41, 0.13] 0.294
Hydration [%, ECW: ICW] Unadjusted 0.88 [−1.51, 3.26] 0.466 1.30 [−1.57, 4.17] 0.371 2.95 [0.02, 5.88] 0.049
Adjusteda 0.94 [−1.37, 3.25] 0.419 1.06 [−1.74, 3.86] 0.454 2.93 [0.08, 5.78] 0.044
aModels were adjusted for age, gender, diagnosis of hematological malignancy and glucocorticoid intake. bData are presented as estimated mean difference between
study groups and 95% confidence intervals [95% CI]. Statistically significant effects are marked in bold type. WB-EMS, whole-body electromyostimulation; FMI, fat mass
index; FFMI, fat free mass index; SMM, skeletal muscle mass, FM, fat mass; PhA, phase angle; ECW, extracellular water; ICW, intracellular water.
Physical Function and Quality of Life
Analysis of physical function, quality of life and fatigue were
based on available pre- and post-assessment data measured at
baseline and after 12 weeks (Table 4). Patients of the WB-
EMS group significantly increased their 6-min-walking distance
FIGURE 3 | Relationship between daily protein intake and change in skeletal
muscle mass. Pearson correlation between daily protein intake (g/kg
bodyweight) and change in skeletal muscle mass (kg) of the control (n = 6)
and the WB-EMS group (n = 9) after 12 weeks. SMM, skeletal muscle mass;
WB-EMS, whole-body electromyostimulation.
after 12 weeks (48.4 ± 51.5 m; p = 0.032), while walking
performance was kept stable in controls, leading to a significant
difference between the study groups (p = 0.046; Table 4). Though
significance level between groups was not reached (p = 0.181),
an increased performance status was reported by the patients of
the WB-EMS group (Karnofsky-Index, 11.1 ± 17.6; p = 0.095).
A comparable increase in patient-reported physical functioning
was observed for both study groups (controls, 11.5 ± 18.3;
WB-EMS group 10.8 ± 22.7; p = 0.957). Interestingly, controls
reported a non-significant decline in social functioning after
12 weeks (−16.6 ± 27.3; p = 0.311), while exercising patients
remained stable (2.0 ± 19.3; p = 0.764), and thus tended to
function better socially (p = 0.183). Both study groups improved
their fatigue symptoms (FACIT and C30 scale), whereby only the
within-group difference of the controls for the FACIT-Fatigue
scale reached statistical significance (11.3 ± 6.6; p = 0.042).
However, no significant inter-group differences between changes
in fatigue were revealed. Global health tended to improve within
the WB-EMS group (10.4 ± 15.6; p = 0.080), but no significant
differences between the groups were detected. Moreover,
symptoms of insomnia significantly declined (−37.0 ± 35.2;
p = 0.014) and nausea/vomiting tended to decrease in the WB-
EMS group (−14.9± 22.8, p = 0.066).
Hematological and Biochemical
Parameters
No significant within- and between-group differences were
detected for hematological blood parameters (Table 5). However,
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TABLE 4 | Physical function and quality of life at baseline and after 12 weeks1.
Outcome measure Study group n Baseline Week 12 Difference p-Valuea p-Valueb
Physical function
SMWT distance [m] Control 6 519.5 ± 66.7 512.1 ± 76.7 −7.4 ± 38.7 0.658 0.046
WB-EMS 8 534.1 ± 76.0 582.6 ± 82.6 48.4 ± 51.5 0.032
STS repetitions Control 5 14.2 ± 3.0 13.4 ± 2.1 −0.8 ± 1.8 0.336 0.429
WB-EMS 6 13.7 ± 2.7 13.5 ± 3.9 −0.2 ± 1.7 0.822
Karnofsky-Index Control 6 73.3 ± 10.3 75.0 ± 5.5 1.7 ± 7.5 0.611 0.181
WB-EMS 9 75.6 ± 15.9 86.7 ± 14.1 11.1 ± 17.6 0.095
Quality of life
FACIT-fatigue scale Control 4 25.5 ± 12.4 36.8 ± 8.8 11.3 ± 6.6 0.042 0.147
WB-EMS 9 35.0 ± 12.5 39.8 ± 11.6 4.8 ± 7.0 0.075
EORTC QLQ-C30
Functional scales
PF Control 4 63.5 ± 32.7 75.0 ± 21.9 11.5 ± 18.3 0.299 0.957
WB-EMS 9 66.0 ± 20.9 76.8 ± 23.4 10.8 ± 22.7 0.192
RF Control 4 60.8 ± 25.7 50.1 ± 19.5 −10.8 ± 18.3 0.570 0.261
WB-EMS 9 49.9 ± 30.1 62.9 ± 20.1 13.0 ± 33.2 0.274
EF Control 4 66.6 ± 26.6 62.3 ± 24.8 −4.3 ± 33.8 0.818 0.710
WB-EMS 9 64.8 ± 35.9 71.2 ± 23.4 6.4 ± 31.3 0.553
CF Control 4 60.4 ± 25.0 66.9 ± 0.2 6.5 ± 25.2 0.641 0.833
WB-EMS 9 81.4 ± 21.1 90.8 ± 14.6 9.3 ± 20.5 0.208
SF Control 4 75.1 ± 9.3 58.5 ± 34.6 −16.6 ± 27.3 0.311 0.183
WB-EMS 9 61.0 ± 25.1 63.0 ± 35.2 2.0 ± 19.3 0.764
Symptom scales
Pain Control 4 29.0 ± 20.9 12.5 ± 15.4 −16.5 ± 13.5 0.092 0.928
WB-EMS 9 44.4 ± 40.7 25.8 ± 35.3 −18.7 ± 45.2 0.250
Dyspnea Control 4 41.5 ± 42.0 41.5 ± 42.0 0.0 ± 0.0 1.000 0.598
WB-EMS 9 36.9 ± 31.0 29.6 ± 42.3 −7.3 ± 40.1 0.598
Insomnia Control 4 58.3 ± 50.1 24.8 ± 16.5 −33.5 ± 38.7 0.157 0.940
WB-EMS 9 48.1 ± 37.8 11.1 ± 23.6 −37.0 ± 35.2 0.014
Appetite loss Control 4 24.8 ± 16.5 16.5 ± 19.1 −8.3 ± 16.5 0.317 0.825
WB-EMS 9 22.2 ± 29.0 18.4 ± 33.8 −3.8 ± 20.0 0.414
Constipation Control 4 33.3 ± 27.4 33.5 ± 38.7 0.3 ± 47.6 0.992 0.414
WB-EMS 9 11.1 ± 23.6 3.7 ± 11.0 −7.4 ± 14.8 0.180
Diarrhea Control 4 8.3 ± 16.5 0.0 ± 0.0 −8.2 ± 16.5 0.317 0.825
WB-EMS 9 11.1 ± 23.6 3.7 ± 11.0 −7.4 ± 27.8 0.414
Financial difficulties Control 4 16.8 ± 33.5 0.0 ± 0.0 −16.8 ± 33.5 0.317 0.503
WB-EMS 9 14.8 ± 24.2 14.8 ± 24.2 0.0 ± 17.0 1.000
Nausea/vomiting Control 4 16.5 ± 19.1 8.3 ± 16.5 −8.3 ± 16.5 0.317 0.710
WB-EMS 9 18.6 ± 25.7 3.7 ± 11.0 −14.9 ± 22.8 0.066
Fatigue Control 4 66.8 ± 24.1 44.3 ± 27.4 −22.5 ± 45.3 0.394 1.000
WB-EMS 9 46.9 ± 23.0 36.9 ± 35.6 −10.0 ± 25.8 0.114
Global Health Control 4 45.8 ± 10.7 64.5 ± 14.2 18.8 ± 21.8 0.184 0.448
WB-EMS 9 61.8 ± 24.0 72.2 ± 18.3 10.4 ± 15.6 0.080
1 Includes patients with pre- and post-assessment data. aPaired-sample t-test for parametric or Wilcoxon-signed-rank test for non-parametric values for comparison of
pre- and post-intervention values. b Independent-samples t-test for parametric or Mann–Whitney U-test for non-parametric values for comparison of pre- to post-test
changes. Statistical significance is indicated by p < 0.05 and marked in bold type. SMWT, 6-min-walking test; STS, 30 s sit-to-stand test; PF, physical functioning; RF,
role functioning; EF, emotional functioning; CF, cognitive functioning; SF, social functioning; WB-EMS, whole-body electromyostimulation.
a distinct decrease in triglyceride concentrations was noticed in
the WB-EMS group (−31.8 ± 68.7; p = 0.232) in contrast to
an increase in the control group (36.3 ± 50.6; p = 0.139), albeit
differences between the groups did not reach level of statistical
significance (p = 0.064).
DISCUSSION
This study is the first study, by our knowledge, that investigated
the impact of a combined physical exercise and nutrition pro-
gram on patients actively treated for hematological malignancies.
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TABLE 5 | Hematological and blood biochemistry parameters at baseline and after 12 weeks1.
Outcome measure Study group n Baseline Week 12 Difference p-Valuea p-Valueb
Hematological parameters
Leukocytes [×103/µl] Control 6 4.27 ± 3.63 3.86 ± 1.86 −0.41 ± 2.83 0.739 0.607
WB-EMS 9 4.85 ± 1.44 4.68 ± 2.23 −0.17 ± 3.21 0.878
Thrombocytes [×103/µl] Control 6 144.3 ± 99.5 155.0 ± 98.5 10.7 ± 23.4 0.316 0.902
WB-EMS 9 183.0 ± 89.1 196.6 ± 85.1 13.6 ± 52.2 0.458
Erythrocytes [×106/µl] Control 6 3.96 ± 0.65 4.30 ± 0.75 0.34 ± 0.74 0.311 0.564
WB-EMS 9 3.79 ± 0.50 3.93 ± 0.44 0.15 ± 0.32 0.206
Hemoglobin [g/dl] Control 6 12.1 ± 1.4 13.3 ± 2.2 1.1 ± 2.3 0.374 0.391
WB-EMS 9 12.1 ± 1.2 12.5 ± 1.0 0.4 ± 0.9 0.225
Hematocrit [%] Control 6 36.1 ± 4.1 39.0 ± 6.0 2.9 ± 6.4 0.312 0.422
WB-EMS 9 35.5 ± 3.8 36.5 ± 2.9 1.0 ± 2.7 0.325
Clinical chemistry
CRP [mg/l] Control 6 3.7 ± 4.1 6.1 ± 12.3 2.4 ± 9.3 0.600 0.388
WB-EMS 9 5.7 ± 5.1 5.2 ± 9.0 −0.5 ± 10.3 0.892
Albumin [g/l] Control 6 40.3 ± 3.3 41.2 ± 4.0 0.9 ± 4.9 0.676 0.896
WB-EMS 8 41.0 ± 3.9 42.2 ± 2.5 1.2 ± 3.0 0.303
Total protein [g/l] Control 6 62.2 ± 6.0 64.0 ± 7.6 1.8 ± 6.2 0.510 0.382
WB-EMS 8 65.5 ± 7.7 64.4 ± 5.2 −1.1 ± 5.7 0.602
Triglycerides [mg/dl] Control 6 130.5 ± 49.6 166.8 ± 58.8 36.3 ± 50.6 0.139 0.064
WB-EMS 8 179.0 ± 54.5 147.3 ± 46.3 −31.8 ± 68.7 0.232
LDH [IU/l] Control 6 183.0 ± 97.2 187.0 ± 48.1 4.0 ± 92.0 0.919 0.657
WB-EMS 9 289.0 ± 112.2 269.7 ± 66.3 −19.3 ± 100.4 0.579
Creatinine [mg/dl] Control 6 0.91 ± 0.19 0.95 ± 0.29 0.04 ± 0.12 0.446 0.916
WB-EMS 9 0.92 ± 0.23 0.97 ± 0.28 0.05 ± 0.10 0.174
1 Includes patients with pre- and post-assessment data. aPaired-samples t-test for parametric or Wilcoxon-signed-rank test for non-parametric values for comparison
of pre- and post-intervention values. b Independent-samples t-test for parametric or Mann–Whitney U-test for non-parametric values for comparison of pre- to post-test
changes. Statistical significance is indicated by p < 0.05 and marked in bold type. WB-EMS, whole-body electromyostimulation; CRP, C-reactive protein; LDH, lactate
dehydrogenase.
We demonstrated that supervised WB-EMS training seems
to be a safe and feasible strength training method for this
patient group. Our results showed a significantly higher
skeletal muscle in the patients additionally trained by WB-
EMS compared to the usual care patients during the 12-week
study course. This strengthens our primary hypothesis that a
combined exercise and nutrition intervention may be more
efficient in maintaining muscle mass during the oncological
treatment in hematological cancer patients than a solely
nutritional support. The dual therapeutic approach also seemed
to induce benefits on the physical functioning and metabolic
risk factors with regard to the lipid metabolism of the
patients.
Body Composition
Patients suffering from cancer are faced to a broad range of
physiological and psychological symptoms resulting in a decline
of physical activity that detrimentally affects body composition
and functional status. The causes are multifactorial and include
disease- and treatment-related toxicities on the cardiopulmonary,
gastrointestinal, neurological and hematopoietic system. As
a consequence of inflammation-mediated metabolic changes,
increased catabolic processes trigger muscle protein breakdown
as a hallmark of cancer cachexia that is mostly prominent in
patients with solid tumors (Fearon et al., 2013). In hematological
cancer, cytotoxic effects of chemotherapeutic agents, radiation,
and immunosuppressive agents may be the main contributors
to the prognostic process of muscle wasting (Blauwhoff-
Buskermolen et al., 2016; Guglielmi et al., 2017). Synthetic
glucocorticoids are widely used within the chemotherapeutic
treatment of lymphoproliferative diseases (Lin and Wang, 2016).
Disadvantageously, glucocorticoids induce a broad range of
catabolic actions and dysregulate anabolic signaling leading
to a loss in skeletal muscle mass and function (Gupta and
Gupta, 2013). Deficits in health-related physical fitness are
therefore common (Persoon et al., 2017b). Increasing the
physical activity of cancer patients during active treatment could
be a key approach to overcome those deficits and preserve
muscle mass. We here provided an novel strength training
method in form of WB-EMS that is time-efficient, gentle
for the patient and was already shown to increase muscle
mass in sarcopenic elderly and patients suffering from chronic
heart failure (Fritzsche et al., 2010; Kemmler et al., 2014).
With the present pilot trial we could emphasize the muscle-
building effect of the WB-EMS training for patients actively
treated for different hematological malignancies. Our results
demonstrated that an additional regular WB-EMS training can
improve skeletal muscle mass with a superior effect to a sole
nutritional support even after 4 weeks of study intervention.
The benefit of this combined 12-week intervention on muscle
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mass maintenance is in line with the results of our previous
study in advanced-stage solid cancer patients (Schink et al.,
2018). Studies evaluating the effect of physical exercise on
skeletal muscle mass as a primary outcome in hematological
cancer patients during active treatment are quite rare. Evidence
of the effectiveness of physical exercise to improve skeletal
muscle mass in hematological cancer was provided by a study
of Coleman et al. (2003), demonstrating a higher muscle mass
for multiple myeloma patients after a 12-week aerobic/resistance
exercise program compared to a control group who only
received advices for an active lifestyle (Coleman et al., 2003).
In contrast, a mixed exercise program consisting of home-
based, gym-based and group-based exercises showed no effect
on fat-free mass index in myeloma patients (Groeneveldt et al.,
2013). Likewise, resistance exercise three or five-times a week
showed no superior impact on arm muscle area compared
to control patients in acute leukemia patients undergoing
bone marrow transplantation and total parenteral nutrition
(Cunningham et al., 1986). Overall, it would be of great interest
to prospectively investigate, if WB-EMS combined with the high
protein nutritional support may be more efficient in improving
the muscle mass status than conventional strength training
methods.
In fact, we observed a strong positive correlation of the
amount of protein intake with an increase in skeletal muscle
mass after 12 weeks in the WB-EMS group. This observation
may suggest that the known hypertrophic effect of physical
exercise, especially in form of resistance training (Schoenfeld,
2010), can be supported and probably enhanced by the additional
anabolic stimuli of a regular high protein/amino acid intake
that helps to efficiently overcome increased catabolic processes
(Willoughby et al., 2007). Tieland et al. (2012) demonstrated that
an additional protein supplementation of 15 g 2×/day showed
a stronger effect on muscle mass gain in older men performing
a progressive resistance training for 24 weeks compared to the
exercising placebo-group. Contrary, no effect of an additional
protein supplementation (40 g/d) on muscle mass gain during
a resistance training program was observed in a study with
breast cancer survivors (Madzima et al., 2017). In this study,
however, patients reached only a mean daily protein intake
of 1.2 g/kg/d in contrast to a mean daily protein intake of
1.4 g/kg/d in our trial and calorie restriction resulted in a
net gain of the protein intake of only 17 g/d. This may have
affected results. However, due to the small sample size and the
lack of an exercise group that was not intended to increase
protein intake, a definitive conclusion about a valid impact
of the amount of protein intake on muscle build up in our
patient population cannot be drawn. Nonetheless, although
our correlation analysis should be interpreted cautiously, it
emphasizes a further investigation of the exact amount of
dietary protein that is needed for muscle build-up in lager-scaled
randomized controlled trials.
In addition to skeletal muscle mass, we also monitored
changes in bodyweight and other body compartments. At
baseline, approximately 60% of our patients were classified
as overweight or obese. Unfavorable body composition
characterized by overweight/obesity as a result of a high
body fat percentage and reduced muscle mass is frequently
observed in patients treated for hematological cancer and hints
toward the presence of the so called sarcopenic obesity (Xiao
et al., 2016; Persoon et al., 2017b). High body fat promotes the
secretion of inflammatory mediators by the adipose tissue leading
to a systemic inflammation and higher oxidative stress level that
trigger the development of metabolic diseases (Nanayakkara
et al., 2012; Ellulu et al., 2017). Thus, sarcopenic obesity can
negatively impact the overall life expectancy (Yip et al., 2015).
Considering this, avoiding deterioration of manifestation of
metabolic disorders of long-term cancer patients should be goal
in a multimodal cancer care. Studies also provide evidence that
high body fat can be predictive for greater dose-independent
side-effects and a worse treatment response (GroDelta et al.,
2017). Our results showed that even though both study groups
tended to increase in bodyweight, this increase was due different
tissues changes. While patients of the WB-EMS group increased
in muscle mass and were balanced in body fat percentage,
control patients were further shifted toward sarcopenic obesity,
underlined by a decrease in muscle mass and an increase in
body fat that was significantly higher at study end. Interestingly,
a trial of Kemmler et al. (2017) demonstrated comparable
results. Older men receiving WB-EMS training and high protein
supplementation (1.7–1.8 g/kg/d) showed a higher reduction of
total body fat and increase of muscle mass than men with isolated
protein supplementation or no intervention. The increase in
body fat during treatment of hematological cancer might be a
result of glucocorticoid treatment affecting the lipid metabolism
(Peckett et al., 2011) in line with low physical activity levels
induced by fatigue (Coleman et al., 2011). Our results therefore
suggest that exercise in form of WB-EMS combined with a high
protein intake could be efficient to attenuate treatment-related
unfavorable body composition changes and may therefore also
be helpful to improve treatment response and avoid metabolic
diseases in the post-treatment period. Underlining this thesis,
we observed changes in serum triglycerides. The lipid profile
of patients with hematological malignancies was shown to
be negatively altered. Concentrations in cholesterol fractions
are suggested to be inversely associated with the incidence of
hematological cancer, while triglycerides can be elevated in those
patients, especially in the active disease period (Naik et al., 2006;
Kuliszkiewicz-Janus et al., 2008). After 12 weeks we recognized
a strong trend toward a decrease in serum triglycerides in
the WB-EMS group in contrast to an increase in the control
group.
During the study course BIA measurements revealed no
statistically significant differences in the nutritional and health-
predicting parameter of phase angle (Lee et al., 2014). Different
glucocorticoid treatments and antidiuretic drugs may have
probably influenced body water distribution that highly affects
phase angle values.
We assessed body composition and thus skeletal muscle
mass by BIA as it was demonstrated to correlate with the
results obtained from Dual Energy X-ray Absorptiometry and
magnetic resonance tomography (Bosy-Westphal et al., 2008;
Bosy-Westphal and Jensen, 2017), but is much easier and faster
to apply, as previously described (Schink et al., 2018).
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Physical Function
Functional disabilities after treatment for hematological cancer
are common and can be observed even years after the
initial therapy (Battaglini, 2011; Tuchman et al., 2015). Several
reviews suggest that muscle strength and physical functioning
can be improved by different exercise interventions in these
patients (Bergenthal et al., 2014; Gan et al., 2016). Our
results support these findings. A significantly higher 6-min-
walking distance and improved patient-reported performance
status (Karnofsky-Index) suggest the effectiveness of WB-EMS
to stabilize and ameliorate the whole muscular status of the
patients by improving functional capacity. In a study with
various hematological cancer patients an exercise program did
not stabilize 6-min-walking distance during HSCT (Takekiyo
et al., 2015), even though exercise was conducted 5 days a
week each time for 40 min. In contrast, Mello et al. (2003)
showed a significant increase in muscle strength 6 weeks after
allogenic bone marrow transplantation. So, either scheduling of
exercise programs or the appropriate intensity and application
type of exercise may be important to relevantly improve physical
function in patients with hematological malignancies. Compared
to the conventional exercise programs the less time-consuming
exercise schedule of our ambulant WB-EMS training program
(2×/week á 20 min) may offer a great advantage to efficiently
sustain physical function in hematological patients even during
active treatment.
Quality of Life
Maintaining of the quality of life is an important goal in a
multimodal cancer care concept. A review of Allart-Vorelli et al.
(2015) demonstrated that different dimensions of quality of life
including physical and psycho-social well-being are detrimentally
affected by hematological malignancies and treatment side-
effects. Fatigue is thereby one of the most burdening symptoms
in these patients (Miltenyi et al., 2010). Physical exercise
was shown to improve physical well-being and to potentially
reduce fatigue-symptoms (Oldervoll et al., 2003; Groeneveldt
et al., 2013). Both of our study groups improved in fatigue,
whereby a greater improvement in the control group was
most likely due to a higher fatigue burden at baseline of
the analyzed patients. However, a recent study with myeloma
and lymphoma patients also showed a decrease in fatigue in
the exercising as well as in the usual care control group,
probably a result of exercise contamination in controls (Persoon
et al., 2017a). Besides physical exercise, also the nutritional
support covering patients’ energy and nutrient requirements
may have relieved fatigue symptoms. The small sample size
makes it difficult to interpret the results conclusively. However,
although there are no significant differences between the
groups, patients of the physical exercise group showed greater
improvements for their psychosocial functioning, indicating
improved social and role functioning. These patients showed also
a distinct increase in global health/overall quality of life after
12 weeks of WB-EMS training. Moreover, intra-group analysis
revealed a significant amelioration of insomnia, a frequent
symptom in hematological cancer patients (Johnsen et al., 2009;
Coleman et al., 2011). Exercise was previously suggested to
be a potent treatment against insomnia (Passos et al., 2012).
Further, a strong trend toward decreased nausea during anti-
cancer treatment was revealed for the WB-EMS group that
could also be demonstrated in exercising breast cancer patients
undergoing adjuvant chemotherapy (Lee et al., 2008) and hints
toward a decreased treatment-related toxicity and adequately
adapted nutrition.
Overall Training Adherence
The implementation of exercise interventions into the clinical
routine, especially for actively treated hematological cancer
patients, is not easy. Many exercise studies were conducted
with solid cancer patients, especially breast and prostate cancer
patients that are relatively fit. However, treatment toxicities
including anemia-induced fatigue, insomnia, and psychological
distress hinders hematologic patients from regular exercise
(Coleman et al., 2003). The high dropout rate in our physical
exercise group of 59.1% underlines this difficulty. Deterioration
in clinical status and treatment toxicities (worsening of acute
GvHD) were the main reasons for study dropouts. Poor state
of health was underlined by the significantly higher daily drug
intake and leukocyte count as well as lower serum albumin
hinting toward decreased nutritional status. Only visiting the
monthly intermediate measurement may have been therefore
less burdening for patients than regularly attending the WB-
EMS exercise sessions that could interfere with disease-related
complications (Oldervoll et al., 2011; Schink et al., 2018).
Nonetheless, patients who completed the 12-week intervention
period of our study showed a good exercise adherence attaining
in mean 77.3% of the scheduled exercise sessions underlining
the good acceptance of the WB-EMS training method. Moreover,
it has to be mentioned that no WB-EMS related adverse
events occurred and that approximately one-third of our
patients suffered from osteolytic lesions, as a complication of
myeloma infiltration. Those patients might not have been able
to undergo a strenuous high intensity apparatus training that
is necessary to build up muscles but can be too risky due to
possible bone fractures. The innovative technology of WB-EMS
to activate almost all large muscle groups simultaneously in
line with gentle, easy-to-perform mild exercises removes those
concerns.
Study Limitations
Even though, baseline characteristics were well balanced between
study groups, the results may be limited by the lack of
randomization and blinding of study patients and assessors,
respectively, as well as by the small sample size that could have
induced bias (Schink et al., 2018). Outcome differences between
the study groups may have been a result of a higher percentage of
more motivated patients in the WB-EMS group, albeit allocation
to study groups was associated to the journey way to the
study center to mostly rule out this problem (Schink et al.,
2018). Hence, randomized controlled trials are now necessary to
confirm our promising results.
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CONCLUSION
Summarizing the results of our pilot study we could demonstrate
that physical exercise in form of WB-EMS seems to be a
feasible and safe strength training method for patients with
hematological malignancies. In combination with individual
nutritional support high in dietary protein WB-EMS potentially
improves skeletal muscle mass and prevents treatment- and
disease-related unfavorable changes in body composition and
fat metabolism. The clinical relevance of our findings may be
emphasized by the observed improvement and preservation of
the physical function by the combined therapeutic approach.
Our preliminary results now encourage the conduction of further
randomized controlled trials with longer follow-up periods to
verify these findings and to investigate the maintenance of
muscle mass und function after the active treatment period of
hematological cancer patients.
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